A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The company’s products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. It has a license agreement with Mount Sinai Health System to develop and commercialize its products in connection with the application of artificial intelligence for the diagnosis of kidney disease. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. The company was incorporated in 2018 and is based in London, the United Kingdom.
Financial Summary
| Share Statistics | RNLXY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $15.6 | $179.6 | 9% |
|
| Shares Out (Mil) | 382.5 | 47.9 | 86% |
|
| Institutional Ownership | 46.3% | 78.6% | 21% |
|
| Float (Mil) | 363.9 | 40.1 | 82% |
|
| Beta | 1.97 | 1.22 | 92% |
|
| Avg Daily Volume (000s) | 6 | 205 | 14% |
|
| Price Change (52-week) |
(62.0%) | 41.0% | 12% |
|
| Growth | RNLXY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.7% | na |
|
| Net Income (5yr) | (15.8%) | (1.0%) | 24% |
|
| EPS (5yr) | 15.3% | 15.5% | 57 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (14.9%) | (15.5%) | 53% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | RNLXY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3 | $192 | 4% |
|
| Net Income (TTM) (Mil) | ($20) | ($9) | 24% |
|
| EPS (TTM) | ($0.052) | ($0.500) | 37% |
|
| Operating Cash Flow (TTM) (Mil) | ($13) | $8 | 17% |
|
| Net Cash Flow (TTM) (Mil) | na | ($3) | na |
|
| Long-Term Debt (Q1) (Mil) | $6 | $14 | 25% |
|
| Enterprise Value (Q1) (Mil) | $12 | $215 | 8% |
|
| Valuation | RNLXY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 1.22 | na |
|
| P/E | na | 36.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 2.0 | na |
|
| Ratios | RNLXY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 45.5% | 61.6% | 57% |
|
| Net Margin | (603.0%) | (29.3%) | 1% |
|
| ROA | (222.7%) | (21.9%) | 2% |
|
| ROE | 439.6% | (1.4%) | 99% |
|
| Liabilities to Assets | 112.1% | 33.3% | 96% |
|
| F-Score | na | 4 | na |
|
Renalytix Plc did not pass any screens on 7/31/2026.
